FRONTIERS IN MEDICINE

Lloyd B. Minor, MD

Carl and Elizabeth Naumann Dean of Stanford University School of Medicine
Professor of Otolaryngology – Head and Neck Surgery

A PREVIEW OF PRECISION HEALTH
How the next generation of medicine at Stanford will leverage the latest science and technology to deliver predictive, preventive, and precise care to every patient.

Lloyd B. Minor, MD, became the Carl and Elizabeth Naumann Dean of Stanford University School of Medicine on December 1, 2012. As dean, Dr. Minor is leading the Campaign for Stanford Medicine, which seeks to Fuel Innovation, Transform Patient Care, and Empower Future Leaders at the school and at Stanford Health Care and Lucile Packard Children’s Hospital Stanford.

With Dr. Minor’s leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in Precision Health. The next generation of health care, Precision Health is focused on keeping people healthy and providing care that is tailored to individual variations. It is predictive, proactive, preemptive, personalized, and patient-centered.

Among his accomplishments, Dr. Minor has led the development of an innovative model for cancer research and patient care delivery at Stanford Medicine and has launched a biomedical data science initiative.

Prior to joining Stanford, Dr. Minor was provost and senior vice president of academic affairs of The Johns Hopkins University.

Dr. Minor received his bachelor’s and medical degrees from Brown University. He trained at Duke University Medical Center and the University of Chicago Medical Center. In 2012, Dr. Minor was elected to the Institute of Medicine of the National Academy of Sciences.
 

Kari Nadeau, MD, PhD

Associate Professor of Medicine (Pulmonary and Critical Care Medicine)
Associate Professor of Pediatrics (Allergy and Clinical Immunology)
Director, Sean N. Parker Center for Allergy Research at Stanford University

STOPPING ALLERGIES BEFORE THEY START
Predicting and preventing allergic disorders with the power of genetics and epigenetics

About one in three Americans suffers from some sort of allergy—whether to food, drugs, the environment, or other triggers. Approximately 25 percent of food-allergy sufferers will have a near-fatal anaphylactic reaction at some point in their lives.

Kari Nadeau, an internationally renowned immunology and allergy researcher, studies the underlying mechanisms involved in allergies to better understand how to prevent and cure the disease. She has led many clinical research studies and developed the first-ever combination, multi-food-allergy therapy shown to safely desensitize food-allergic patients.

It was because of her remarkable work that the new Parker Center was brought to Stanford last year under her direction to propel innovation in allergy research; it is the first of its kind in the world.

Dr. Nadeau’s work has been recognized with numerous grants and awards, and her research is part of a prestigious Clinical and Translational Science Award from the National Institutes of Health.

Dr. Nadeau received her MD and PhD from Harvard Medical School. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford and University of California, San Francisco. She has been a faculty member at Lucile Packard Children’s Hospital Stanford since 2006. 

Garry Nolan, PhD

Rachford and Carlota A. Harris Professor
Professor of Microbiology and Immunology

A MILLION ANSWERS IN EVERY CELL
Super sensitive new tools can gather gigabytes of data from a single cell to enable unprecedented precision in research and treatment

Stanford researchers recently found that they could predict how well a patient would recover from surgery, based on the activity of a specific set of immune cells.

They were able to make this discovery because they used a highly sensitive technology called single-cell mass cytometry developed by Garry Nolan, PhD. The method enables simultaneous monitoring of large numbers of biochemical features both on the surfaces of immune cells and within the cells, telling scientists not only what kind of cells they are looking at, but how active they are.

With this tool, Dr. Nolan is making unprecedented leaps in our understanding not only of normal immune function, but also cancer and leukemia, autoimmunity and inflammation, hematopoiesis, and the immune system’s response to trauma.

Dr. Nolan received his undergraduate degree in biology and genetics from Cornell University and his PhD in genetics from Stanford University. He performed postdoctoral work at Stanford in the lab of Dr. Leonard Herzenberg, as well as at MIT and Cambridge/Rockefeller University. He has received numerous honors and awards, including the Teal Innovator Award.

Nobel Laureate Michael Levitt, PhD

Robert W. and Vivian K. Cahill Professor of Cancer Research
Professor of Structural Biology

PRECISION AT THE MOLECULAR LEVEL
Unraveling the basic mechanisms of life to transform human health

Considered a true pioneer in science, Michael Levitt was one of the first individuals to apply the power of computers to the complexity of biology.

He has dramatically advanced the field of structural biology. As a pioneer in computer modeling for biology, he builds precise models of molecules at life’s most fundamental level, a necessary first step in understanding how the molecules work and in designing drugs to alter their function.

His 2013 Nobel Prize in Chemistry recognizes the value of basic science research to practical medicine: his work has led to methods that are crucial for modern anticancer therapy.

Effortlessly crossing the disciplines of computer science, physics, and biology, he is considered to be the perfect model of the interdisciplinary scientist that makes Stanford Medicine great.

Dr. Levitt received his PhD from Cambridge University. He was a postdoctoral scholar at the Weizmann Institute of Science in Israel and then studied at the Salk Institute.

He came to Stanford in 1987 and is the former chair and associate chair of the Department of Structural Biology. He is a fellow of the Royal Society and a member of the American Academy of Arts and Sciences and the National Academy of Sciences.

Amir Dan Rubin

President and CEO, Stanford Health Care

DELIVERING ON THE PROMISE OF PRECISION HEALTH
How our expanding network of state-of-the-art facilities and world-class providers will make Precision Health a reality

Amir Dan Rubin serves as president and CEO of Stanford Health Care, a $3 billion academic health system affiliated with Stanford University. Stanford Health Care seeks to serve humanity through science and compassion, one patient at a time, through its commitment to care, educate, and discover.

Stanford Health Care delivers the benefits of clinical innovation with highest levels of care and compassion across its inpatient services, specialty health centers, physician offices, virtual care offerings, and health plan programs. Stanford is widely recognized for breakthroughs in treating cancer, heart disease, brain disorders, and surgical and medical conditions.

At Stanford Health Care, Rubin has worked with a broad team to raise patient experience scores to the 95^th percentile in the nation, advance quality performance, grow a regional network of inpatient and outpatient settings, launch health plan offerings, advance digital health innovation, and deploy the Stanford Operating System for lean management.

Prior to Stanford, Rubin served as chief operating officer for the UCLA Health System. In 2014 he was recognized with the Ernst & Young Entrepreneur of the Year Award in Northern California amongst large companies.

He earned a master’s degree in Health Services Administration as well as a master’s degree in Business Administration from the University of Michigan, and a bachelor’s degree in Economics with a minor in Business Administration from the University of California, Berkeley.